证券代码：300206 证券简称：理邦仪器 公告编号：2025-009 深圳市理邦精密仪器股份有限公司 关于使用闲置自有资金购买短期保本理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司 为提高资金使用效率，合理利用闲置资金，增加公司收益，2025 年 4 月 23 日，深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届董事会 2025 年第一次会议审议通过了《关于使用闲置自有资金购买短期保本理财产品》的议 案。在保证正常生产经营不受影响和风险可控的前提下，公司董事会同意使用不 超过人民币 6 亿元的闲置自有资金购买短期保本理财产品，现将有关事项公告如 下： 一、投资概况 1、投资目的 为提高公司资金使用效率，合理利用闲置资金，在不影响公司正常经营的情 况下，利用闲置自有资金购买保本型理财产品，增加公司收益，为公司及股东谋 取较好的投资回报。 2、投资额度 公司使用额度不超过人民币 6 亿元的闲置自有资金购买保本型理财产品。在 上述额度内，资金可以滚动使用。 3、投资品种 此次投资品种为一年以内的保本理财产品， ...

深圳市理邦精密仪器股份有限公司 深圳市理邦精密仪器股份有限公司 1 董事会审计委员会关于对会计师事务所2024年度履职情况 评估及履行监督责任情况的报告 深圳市理邦精密仪器股份有限公司（以下简称"公司"）董事会审计委员会 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》 《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公司 自律监管指引第2号——创业板上市公司规范运作》等法律法规、规范性文件以 及《公司章程》《董事会审计委员会工作细则》等规定和要求，本着勤勉尽责的 原则，恪尽职守，认真履职。现将董事会审计委员会对会计师事务所2024年度履 职评估及履行监督职责的情况汇报如下： 一、2024年年审会计师事务所基本情况 （一） 会计师事务所基本情况 名称：信永中和会计师事务所（特殊普通合伙）（以下简称"信永中和"） 成立日期：2012年3月2日 组织形式：特殊普通合伙企业注册地址：北京市东城区朝阳门北大街8号富 华大厦A座8层 首席合伙人：谭小青先生 截至2024年12月31日，信永中和合伙人259人，注册会计师1780人。签署过 证券服务业务审计报告的注册会计师人数超过 ...

Revenue and Profit - Revenue for Q1 2025 was CNY 420,355,229.15, a decrease of 5.25% compared to CNY 443,644,512.37 in the same period last year[4] - Net profit attributable to shareholders increased by 68.98% to CNY 65,088,179.59 from CNY 38,517,609.83 year-on-year[4] - Basic and diluted earnings per share rose by 69.13% to CNY 0.1123 from CNY 0.0664 in the same period last year[4] - Net profit for the current period is ¥65,179,960.42, an increase of 67.5% compared to ¥38,866,635.68 in the previous period[32] - The company reported a total profit of ¥65,075,313.25, which is an increase of 64.5% from ¥39,580,516.66 in the previous period[32] - The company’s total comprehensive income for the current period is ¥64,996,759.94, up from ¥38,892,554.21 in the previous period, marking a growth of 67.2%[32] Cash Flow and Operating Activities - The net cash flow from operating activities decreased significantly by 86.46% to CNY 10,519,560.71 from CNY 77,719,605.62 in the previous year[21] - Cash flow from operating activities generated a net amount of ¥10,519,560.71, a significant decrease of 86.5% from ¥77,719,605.62 in the previous period[34] - The company’s investment activities resulted in a net cash outflow of ¥321,761,437.53, compared to a net outflow of ¥209,433,647.81 in the previous period[36] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,378,193,094.84, a decrease of 0.79% from CNY 2,397,044,407.74 at the end of the previous year[4] - The company's total liabilities decreased to CNY 305,437,345.35 from CNY 389,285,418.19, indicating a reduction of approximately 21.5%[29] - Cash and cash equivalents decreased to CNY 815,521,494.80 from CNY 1,123,799,045.12, representing a decline of approximately 27.4%[28] - The total non-current assets slightly decreased to CNY 711,307,853.62 from CNY 712,738,237.21, indicating a marginal decline[29] - The company reported a total of 1,666,885,241.22 in current assets, down from 1,684,306,170.53, a decrease of approximately 1.4%[28] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,431[24] - The total equity attributable to the parent company increased to CNY 2,073,332,816.64 from CNY 2,008,426,242.90, reflecting a growth of about 3.2%[30] - The company's retained earnings increased to CNY 954,139,879.05 from CNY 896,340,313.10, reflecting an increase of about 6.5%[29] Inventory and Receivables - Accounts receivable increased slightly to CNY 147,828,046.36 from CNY 145,953,596.03, showing a growth of about 1.3%[28] - Inventory decreased to CNY 337,643,309.64 from CNY 351,912,330.97, indicating a reduction of approximately 4.0%[28] Investment Income and Impairment Losses - Investment income surged by 569.03% to CNY 998,408.81 compared to a loss of CNY 212,867.73 in the same period last year[15] - The company experienced a 812.84% increase in credit impairment losses, amounting to CNY -850,359.19, due to increased provisions for accounts receivable[17] - The company incurred a credit impairment loss of ¥850,359.19, compared to a loss of ¥93,155.29 in the previous period[31]

Product Innovation and Development - In 2024, the company launched the i500 wet blood gas analyzer, significantly reducing testing time and optimizing sample processing, enhancing medical efficiency and patient experience [6]. - The company has launched several strategic new products, including the i500 fully automatic blood gas electrolyte analyzer and the Nano series handheld digital ultrasound diagnostic device, enhancing its product competitiveness [112]. - The company has developed the industry-first CNBP continuous non-invasive blood pressure measurement technology, widely accepted by top-tier hospitals [60]. - The company launched a comprehensive blood gas solution that includes a full range of products and a smart POCT software management platform, addressing pain points in traditional blood gas testing [85]. - The company aims to enhance brand influence and channel coverage while expanding ECG network coverage and promoting international localization [66]. - The company is developing a new product, the Six-Minute Walk Test System, aimed at expanding its ECG product line [162]. - The company is focusing on technological advancements, as evidenced by the registration of a new ECG system (Class IIa) designed for both adult and pediatric patients, effective from December 25, 2024 [180]. - The company is actively pursuing regulatory approvals for new products, with several devices set to expire between 2025 and 2029, ensuring a pipeline of future offerings [171]. Financial Performance - The company's operating revenue for 2024 was ¥1,834,376,591.62, a decrease of 5.35% compared to ¥1,937,988,917.83 in 2023 [32]. - Net profit attributable to shareholders for 2024 was ¥162,109,421.89, down 26.75% from ¥221,301,109.00 in 2023 [32]. - Basic earnings per share for 2024 were ¥0.2797, reflecting a decline of 26.74% from ¥0.3818 in 2023 [32]. - The company achieved operating revenue of 1,834.38 million yuan, a year-on-year decrease of 5.35%, with net profit attributable to shareholders of 162.11 million yuan, down 26.75% [120]. - Domestic market revenue was 736.22 million yuan, down 24.82%, while international market revenue reached 1,098.16 million yuan, an increase of 14.54% [121]. - The total non-recurring gains and losses amounted to CNY 18,455,169.03, a decrease from CNY 26,828,387.65 in the previous year, showing a reduction in non-recurring income [38]. - The company reported a net loss from investment activities of CNY 73,692,586.61, a 53.43% increase in losses compared to the previous year [192]. Market Expansion and Localization - The company achieved a nearly 90% localization rate for overseas employees, demonstrating commitment to local talent and international market penetration [8]. - The company established subsidiaries in Indonesia and France in 2024, improving overseas operations and market responsiveness [8]. - The company will continue to deepen localization efforts in key overseas markets, enhancing market penetration and resource integration [13]. - The company has established a global marketing network covering 34 domestic provinces and over 170 countries, continuously optimizing its marketing layout [115]. - The company has launched the Acclarix Nano series handheld ultrasound solution, focusing on maternal and fetal health in low to middle-income countries [163]. Research and Development - The company has invested over 2.71 billion yuan in R&D since its listing, with R&D expenditure for the reporting period amounting to 340.24 million yuan, accounting for 18.55% of the current operating income [112]. - The company holds a total of 1,243 valid patents, including 523 invention patents, 469 utility model patents, and 251 design patents, with 165 new patents granted during the reporting period [112]. - The company is committed to continuous investment in the IVD field, enhancing product performance and expanding product categories to strengthen its competitive advantage [89]. - The company has established four major R&D centers and 22 subsidiaries globally, focusing on continuous innovation and advanced technology development [57]. - The company is enhancing its research and development efforts, focusing on innovative medical devices such as a remote monitoring system (Class III) for real-time physiological data transmission, registered on September 23, 2024 [178]. Social Responsibility and Compliance - The company is committed to fulfilling social responsibilities while providing high-quality medical products and services [11]. - The company has established a compliance department in August 2024 to ensure adherence to international trade regulations and enhance risk management across key business areas [131]. - The company has received NMPA and EU MDR CE certifications for its blood gas analyzers, enhancing its competitive strength in the blood gas analysis field [84]. - The company has received regulatory approval for multiple diagnostic kits, including the ultra-sensitive C-reactive protein assay kit and D-dimer assay kit, with approval numbers 20222400538 and 20172401776 respectively [175]. Operational Efficiency - The company aims to improve operational efficiency by optimizing resource allocation and shortening product development cycles in 2025 [12]. - The cash flow from operating activities increased significantly by 145.99% to ¥371,360,642.18 in 2024, compared to ¥150,964,260.88 in 2023 [32]. - The company reported a significant increase in cash flow, indicating improved operational efficiency and potential for future investments [32]. - The company has optimized its organizational structure and established new subsidiaries in Indonesia to strengthen its global business layout [130]. Industry Trends and Market Outlook - The global medical device market is projected to reach USD 629.2 billion in 2024, with a compound annual growth rate (CAGR) of 5.71% until 2027 [42]. - China's medical device market is expected to reach CNY 1.15 trillion in 2024, with a CAGR of 10.2% from 2021 to 2025, indicating robust growth potential [47]. - The aging population in China is projected to reach 22% of the total population by 2040, driving increased demand for medical devices related to chronic disease management [49]. - The medical device industry is experiencing rapid growth, driven by increasing health demands, aging populations, and government policies favoring innovation and accelerated approvals [108].

关于召开 2024 年度股东大会的通知 证券代码：300206 证券简称：理邦仪器 公告编号：2025-013 深圳市理邦精密仪器股份有限公司 关于召开2024年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届董事会 2025 年 第一次会议决议决定于 2025 年 5 月 15 日（星期四）在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开 2024 年度股东大会。现将本次会 议有关事项通知如下： （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 5 月 15 日上午 9:15 - 9:25，9:30-11:30，下午 13:00—15:00；通过 1 关于召开 2024 年度股东大会的通知 一、 召开会议的基本情况 1、 股东大会届次：2024 年度股东大会 2、 股东大会的召集人：公司第五届董事会 3、会议召开的合法、合规性： 公司于 2025 年 4 月 23 日召开的第五届董事会 2025 年第一次会议审议通过 了《关 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-008 深圳市理邦精密仪器股份有限公司 第五届监事会 2025年第一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届监事会 2025 年第一次会议于 2025 年 4 月 23 日（星期三）11:30 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2025 年 4 月 11 日 以电子邮件方式发出。会议应出席监事 3 名，实际出席监事 3 名。本次会议召开 符合《公司法》及《公司章程》的相关规定。会议由监事会主席周纯女士主持， 出席会议的监事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《关于 2024 年年度报告及其摘要》的议案； 经审核，监事会认为董事会编制和审核公司《2024 年年度报告》的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 《2024 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-007 深圳市理邦精密仪器股份有限公司 第五届董事会 2025年第一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届董事会 2025 年第一次会议于 2025 年 4 月 23 日（星期三）10:00 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2025 年 4 月 11 日 以电子邮件方式发出。会议应出席董事 7 名，实际出席董事 7 名。本次会议召开 符合《公司法》及《公司章程》的相关规定。会议由董事长张浩先生主持，出席 会议的董事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《关于 2024 年年度报告及其摘要》的议案； 《2024 年年度报告》、《2024 年年度报告摘要》及《2024 年年度报告披露提 示性公告》详见巨潮资讯网，《2024 年年度报告披露提示性公告》同时刊载于中 国证券报和证券时报。 公司董事会审计委员会已审议通过了该 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-014 深圳市理邦精密仪器股份有限公司 关于公司2024年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）于2025年4月23日召 开第五届董事会2025年第一次会议、第五届监事会2025年第一次会议分别审议通 过了《关于2024年度利润分配预案》的议案，本议案尚需提交公司2024年度股东 大会审议。现将该议案的基本情况公告如下： 一、利润分配预案基本情况 1、分配基准：2024 年度。 2、经信永中和会计师事务所（特殊普通合伙）审计，公司2024年度实现归属 于母公司所有者的净利润为162,109,421.89元，根据《公司章程》的有关规定，公 司按照2024年度母公司净利润的10%提取法定盈余公积人民币17,392,050.23元， 截至2024年12月31日，母公司累计可分配利润为人民币987,049,971.71元，合并报 表累计未分配利润为人民币896,340,313.10元。 3、公 ...

4月9日，理邦仪器今日收盘10.7元，上涨1.81%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到39.66倍，总市值62.02亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.15倍，行业中值28.66倍，理邦仪器排 名第84位。 资金流向方面，4月9日，理邦仪器主力资金净流出263.75万元，近5日总体呈流出状态，5日共流出 410.33万元。 深圳市理邦精密仪器股份有限公司主营业务为医疗电子设备产品和体外诊断产品的研发、生产、销售、 服务。主要产品包括病人监护、心电诊断、妇幼健康、超声影像、体外诊断、智慧医疗。在深圳市人力 资源和社会保障局、深圳市中小企业服务局、深圳市工商联的指导下，由深圳市商业联合会、深圳市一 览网络股份有限公司共同主办的第八届深圳成长型企业最佳雇主评选活动中，公司在200多家企业中脱 颖而出，荣获"最佳雇主"荣誉，充分体现了公司"以人为本"的核心价值观。 最新一期业绩显示，2024年三季报，公司实现营业收入13.82亿元，同比-9.29%；净利润1.72亿元，同 比-27.41%，销售毛利率58.17%。 序号股票简称PE(TTM)PE(静)市净率 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-004 深圳市理邦精密仪器股份有限公司 关于董事会换届选举暨征集候选人的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届董事会任期 将于 2025 年 4 月 19 日届满。为了顺利完成本次董事会的换届选举（以下简称 "本次换届选举"），公司董事会依据《公司法》、《深圳证券交易所创业板股票上 市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》、《上市公司独立董事管理办法》等法律法规、规范性文件及《公司章 程》的有关规定，现将第六届董事会的组成、选举方式、董事候选人的推荐、本 次换届选举的程序、董事候选人任职资格等事项公告如下： 一、第六届董事会的组成 公司第六届董事会将由 7 名董事组成，其中独立董事 3 名，设董事长 1 名。 董事任期自相关股东大会选举通过之日起计算，任期三年。 二、选举方式 本次换届选举采用累积投票制，即股东大会选举董事时，每一股份拥有与拟 ...